Chiesi Completes KalVista Acquisition, Expands Rare Disease Portfolio
Chiesi Group has completed its acquisition of KalVista Pharmaceuticals, marking a significant expansion of its rare diseases business and adding a recently approved hereditary…
Read More...
Read More...
